Volagidemab 是一种拮抗性胰高血糖素受体 (GCGR)单克隆抗体 (mAb)。Volagidemab 可用于1型糖尿病 (T1D) 的研究。
| 生物活性 | Volagidemab is an antagonisticglucagon receptor(GCGR)monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D)[1][2]. |
体内研究
(In Vivo) | Volagidemab (5 mg/kg，皮下注射) 在四氧嘧啶诱导的糖尿病小鼠中抑制 1 型糖尿病表型[2]。
| Animal Model: | Alloxan-induced diabetic mice[2] | | Dosage: | 5 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Reduced phosphorylated CREB protein and PEPCK protein expression to nondiabetic levels. |
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
